Rivas, S.; Sepúlveda, R.V.; Tapia, I.; Estay, C.; Soto, V.; Blanco, A.; González, E.; Armisen, R.
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients. Int. J. Mol. Sci. 2024, 25, 13715.
https://doi.org/10.3390/ijms252413715
AMA Style
Rivas S, Sepúlveda RV, Tapia I, Estay C, Soto V, Blanco A, González E, Armisen R.
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients. International Journal of Molecular Sciences. 2024; 25(24):13715.
https://doi.org/10.3390/ijms252413715
Chicago/Turabian Style
Rivas, Solange, Romina V. Sepúlveda, Ignacio Tapia, Catalina Estay, Vicente Soto, Alejandro Blanco, Evelin González, and Ricardo Armisen.
2024. "MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients" International Journal of Molecular Sciences 25, no. 24: 13715.
https://doi.org/10.3390/ijms252413715
APA Style
Rivas, S., Sepúlveda, R. V., Tapia, I., Estay, C., Soto, V., Blanco, A., González, E., & Armisen, R.
(2024). MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients. International Journal of Molecular Sciences, 25(24), 13715.
https://doi.org/10.3390/ijms252413715
